Attached files
file | filename |
---|---|
8-K - NEKTAR THERAPEUTICS | v167930_8k.htm |
EX-10.1 - NEKTAR THERAPEUTICS | v167930_ex10-1.htm |
Exhibit
99.1
News
Release
Nektar
Therapeutics Promotes Lorianne Masuoka, M.D.
To
Senior Vice President and Chief Medical Officer
SAN
CARLOS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq:
NKTR) today announced the promotion of Lorianne Masuoka, M.D. to Senior Vice
President and Chief Medical Officer. Dr. Masuoka will report directly
to Nektar's President and Chief Executive Officer, Howard W. Robin.
"Lorianne's
outstanding leadership and highly effective clinical development strategies have
been instrumental in rapidly advancing Nektar's proprietary clinical pipeline,
including the successful partnering of NKTR-118 with AstraZeneca," Robin
said. "She has assembled a world-class Clinical Development team that
has demonstrated its ability to efficiently and repeatedly move our high-value
proprietary compounds through clinical development."
Dr.
Masuoka has over 15 years of experience in clinical research and development in
CNS, oncology, metabolic disease and immunology. As Senior Vice
President and Chief Medical Officer, she will lead Clinical Development,
Regulatory Affairs, Drug Safety, Clinical Pharmacology, Toxicology and Program
Management.
Dr.
Masuoka joined Nektar in August 2008 as Vice President of Clinical Development.
Dr. Masuoka received her B.S. and M.D. from the University of California, Davis
and completed her fellowship at the Yale School of Medicine. She is
board certified in Neurology.
Dr.
Randall Moreadith, Senior Vice President and Chief Development Officer, will be
leaving the company for personal reasons. The company wishes to
acknowledge his contributions over the past year.
About
Nektar
Nektar
Therapeutics is a biopharmaceutical company developing novel therapeutics based
on its PEGylation and advanced polymer conjugation technology platforms.
Nektar's technology and drug development expertise have enabled nine approved
products in the U.S. or Europe for leading biopharmaceutical company partners,
including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's
PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.
Nektar
has created a robust pipeline of potentially high-value therapeutics to address
unmet medical needs by leveraging and expanding its technology platforms to
improve and enable molecules. Nektar is currently conducting clinical and
preclinical programs in oncology, pain and other therapeutic areas. Nektar
recently entered into an exclusive worldwide license agreement with AstraZeneca
for its oral NKTR-118 program to treat opioid-induced constipation and its
NKTR-119 program for the treatment of pain without constipation side effects.
NKTR-102, PEGylated irinotecan, is currently being evaluated in Phase 2 clinical
studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105,
PEGylated docetaxel, is currently in a Phase 1 clinical study in cancer patients
with refractory solid tumors.
Nektar is
headquartered in San Carlos, California, with additional R&D operations in
Huntsville, Alabama and Hyderabad, India. Further information about the company
and its drug development programs and capabilities may be found online at http://www.nektar.com.
This
press release contains forward-looking statements that reflect management's
current views regarding the value and potential of Nektar's technology platform,
Nektar's pipeline of product candidates in development, and Nektar's
collaborations with third parties. These forward-looking statements
involve risks and uncertainties, including but not limited to: (i) Nektar's
proprietary product candidates and those of its partners are in the early to
mid-stage phases of clinical development and the risk of failure is high and can
occur at any stage prior to regulatory approval; (ii) Nektar or its partners may
not be able to successfully obtain regulatory approval for product candidates in
development; (iii) Nektar's commercialization partners may not be successful in
their sales and marketing efforts even if current product candidates
successfully receive future regulatory approval in one or more markets; (iv)
Nektar's patent applications for its technology platforms and proprietary or
partner product candidates may not issue, patents that have issued may not be
enforceable; and or intellectual property licenses from third parties may be
required in the future; and (v) other important risks and uncertainties set
forth in Nektar's most recent Quarterly Report on Form 10-Q filed on November 5,
2009 and its Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 6, 2009. Actual results could differ materially from the
forward-looking statements contained in this press release. Nektar
undertakes no obligation to update forward-looking statements, whether as a
result of new information, future events or otherwise.
For more
information on Nektar Therapeutics, please visit www.nektar.com
Jennifer
Ruddock, 650-631-4954
CONTACT: Jennifer
Ruddock of Nektar Therapeutics, +1-650-631-4954